Vanda Pharmaceuticals (LTS:0LKB) Shiller PE Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0LKB Vanda Pharmaceuticals Inc LTS:0LKB
63 GF Score
Price $5.16
GF Value $5.55
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Vanda Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Vanda Pharmaceuticals  (LTS:0LKB) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Vanda Pharmaceuticals Shiller PE Ratio Related Terms


Vanda Pharmaceuticals Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Vanda Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vanda Pharmaceuticals Shiller PE Ratio Chart

Vanda Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 296.04 37.90 14.35 24.44 -

Vanda Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.65 33.95 - - -

LTS:0LKB vs IMRX, PRQR, NWBO: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Vanda Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vanda Pharmaceuticals Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vanda Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Vanda Pharmaceuticals's Shiller PE Ratio falls into.


LTS:0LKB
63GF Score
Vanda Pharmaceuticals Inc LTS:0LKB
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vanda Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Vanda Pharmaceuticals's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Vanda Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-1.038/333.9520*333.9520
=-1.038

Current CPI (Jun. 2026) = 333.9520.

Vanda Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 -0.010 241.428 -0.014
201612 -0.010 241.432 -0.014
201703 -0.172 243.801 -0.236
201706 -0.030 244.955 -0.041
201709 -0.100 246.819 -0.135
201712 -0.041 246.524 -0.055
201803 0.064 249.554 0.085
201806 0.086 251.989 0.113
201809 0.131 252.439 0.173
201812 0.188 251.233 0.249
201903 -0.012 254.202 -0.015
201906 0.211 256.143 0.275
201909 1.841 256.759 2.395
201912 0.077 256.974 0.100
202003 0.009 258.115 0.012
202006 0.158 257.797 0.205
202009 0.108 260.280 0.138
202012 0.147 260.474 0.189
202103 0.153 264.877 0.193
202106 0.170 271.696 0.208
202109 0.136 274.310 0.166
202112 0.124 278.802 0.148
202203 -0.115 287.504 -0.133
202206 0.045 296.311 0.051
202209 0.057 296.808 0.065
202212 0.120 296.797 0.135
202303 0.057 301.836 0.063
202306 0.026 305.109 0.029
202309 0.002 307.789 0.003
202312 -0.042 306.746 -0.045
202403 -0.072 312.332 -0.077
202406 -0.078 314.175 -0.082
202409 -0.091 315.301 -0.097
202412 -0.084 315.605 -0.089
202503 -0.504 319.799 -0.526
202506 -0.461 322.561 -0.477
202509 -0.382 324.800 -0.393
202512 -2.389 324.054 -2.462
202603 -0.817 330.213 -0.826
202606 -1.038 333.952 -1.038

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Vanda Pharmaceuticals (LTS:0LKB) Overvalued in 2026?

Based on GuruFocus' analysis, Vanda Pharmaceuticals stock appears to be undervalued. The current stock price of $5.16 is trading 7.1% below its estimated GF Value™ of $5.55. GuruFocus considers Vanda Pharmaceuticals to be Fairly Valued.

Key valuation signals for LTS:0LKB:

  • Shiller PE Ratio:
  • GF Value™: $5.55 vs. price of $5.16 (7.1% below fair value)
  • GF Score™: 63/100 with 4 warning signs

No single metric tells the full story. See the LTS:0LKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vanda Pharmaceuticals Business Description

Other Exchanges VNDA:USAVM4:Germany
Address 2200 Pennsylvania Avenue North West, Suite 300 E, Washington, DC, USA, 20037
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
63GF Score

Get the complete analysis for LTS:0LKB

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.16
Price
$5.55
GF Value